Ignite Creation Date:
2025-12-24 @ 1:42 PM
Ignite Modification Date:
2026-02-20 @ 6:42 PM
Study NCT ID:
NCT02984995
Status:
COMPLETED
Last Update Posted:
2020-02-17
First Post:
2016-12-05
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
Sponsor:
Daiichi Sankyo Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-12-08
Start Date Type:
ACTUAL
Primary Completion Date:
2018-03-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-09-14
Completion Date Type:
ACTUAL
First Submit Date:
2016-12-05
First Submit QC Date:
None
Study First Post Date:
2016-12-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-09-25
Results First Submit QC Date:
None
Results First Post Date:
2020-02-17
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2019-03-18
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2020-02-04
Last Update Post Date:
2020-02-17
Last Update Post Date Type:
ACTUAL